ENOVEnovis Corporation
Is the price fair?
Neither cheap nor expensive: modest expectations priced in, but at the top of its own P/E range.
Priced for ~5% a year FCF growth. The price demands less than its three-year revenue growth of 12% a year, expectations look modest.
Expensive vs its own history: P/E 109.7 vs a 21.7 median over 20 quarters (+406% vs median).
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What ENOV's price assumes
Enovis Corporation did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 0.53× revenue.
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 5.2%
Free cash flow yield · Medical Devices median 4.0%
- Growth the price implies
- +5.0%
Growth the price implies · The price pays for +5.0% free cash flow growth a year for a decade; revenue has grown 12% a year over the last three.
- Price / book
- 0.82
Price / book · today's price, trailing year to Jul 3, 2026
Details›
- Price / booktoday's price, trailing year to Jul 3, 2026
- 0.82
- EV / EBIToperating margin −45%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, trailing year to Jul 3, 2026
- 1.08
- Free cash flow, trailing twelve months
- $64M
- Market capitalisation57.7 million shares, counted Jul 31, 2026
- $1.22B
- 3-year revenue growth
- +12%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
What is it worth?
Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.
Against its own past
Its multiples now against their own history, and how much of the price move came from earnings rather than the multiple.